Subcutaneous administration of modified factor IX polypeptides and treatment of hemophilia B
US11491212B1 · kind B1 · utility
0Cited by
17References
27Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Sep 27, 2018 |
| Grant date | Nov 8, 2022 |
| Priority date | — |
| Expiry date | Sep 27, 2038 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P7/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods for prophylactic treatment of hemophilia B are provided in which modified FIX polypeptides, particularly FIXa, are subcutaneously administered daily or less frequently, such as every other day, or every 2, 3 or 4 days. The treatment results in normal coagulation pharmacokinetics and normal levels of FIX, or mild hemophilia B.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.